Tim Ruan resigned from Indaptus Therapeutics’ board effective immediately after notifying directors on September 2, 2026. For investors, the change alters the board’s membership, while the stated circumstances do not connect his departure to disagreement over the company’s operations, policies or practices.

Key Highlights

  • Tim Ruan’s departure was not the result of disagreement with Indaptus Therapeutics over operations, policies or practices.
  • Chief Executive Officer Junyi Dai signed the company’s report on September 4, 2026.
  • Ruan notified Indaptus Therapeutics’ Board of Directors before the resignation took effect.

Tim Ruan’s Directorship Ends Immediately

Ruan notified the board of his decision that day. The resignation concerned Ruan’s position as a director at Indaptus Therapeutics. The company stated that his departure was unrelated to any disagreement involving its operations, policies or practices. The company’s report was signed by Chief Executive Officer Junyi Dai on September 4, 2026. Dai signed on behalf of Indaptus Therapeutics, Inc. (NASDAQ: INDP) The reported Leadership change therefore concerns a board resignation effective from September 2, 2026.